Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 11054
Country/Region: Democratic Republic of the Congo
Year: 2016
Main Partner: Population Services International
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $2,794,046 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $46,927
Care: Orphans and Vulnerable Children (HKID) $335,356
Care: TB/HIV (HVTB) $150,000
Care: Pediatric Care and Support (PDCS) $7,500
Laboratory Infrastructure (HLAB) $70,000
Strategic Information (HVSI) $100,000
Health Systems Strengthening (OHSS) $150,000
Biomedical Prevention: Injection Safety (HMIN) $100,000
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $308,340
Sexual Prevention: Other Sexual Prevention (HVOP) $365,968
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $249,901
Treatment: Adult Treatment (HTXS) $763,742
Treatment: Pediatric Treatment (PDTX) $146,312
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 806
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,160
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 27,052
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 22,035
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 51,053
HTS_TST Service Delivery Point (Community): Mobile testing 2017 11,153
HTS_TST Service Delivery Point (Facility): Outpatient 2017 20,124
HTS_TST Service Delivery Point (Facility): PMTCT 2017 11,740
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,845
HTS_TST Service Delivery Point (Facility): VCT 2017 6,191
HTS_TST Sum of Aggregated Age/Sex <15 2017 1,966
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 49,087
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 51,053
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 35
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 51
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 956
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 970
OVC_SERV Age/Sex: 18+ Female 2017 902
OVC_SERV Age/Sex: 18+ Male 2017 601
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 833
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 555
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 2,891
OVC_SERV Sum of Age/Sex disaggregates 2017 1,503
PMTCT_ART New on ART 2017 268
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 11,740
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 268
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 6
PMTCT_EID Sum of Infant Age disaggregates 2017 268
PMTCT_STAT By: Number of new positives identified 2017 282
PMTCT_STAT Number of new ANC and L&D clients 2017 11,754
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 11,740
PMTCT_STAT Sum of Positives Status disaggregates 2017 282
PP_PREV Aggregated Age/sex: <15 Female 2017 139
PP_PREV Aggregated Age/sex: <15 Male 2017 93
PP_PREV Aggregated Age/sex: 15+ Female 2017 7,736
PP_PREV Aggregated Age/sex: 15+ Male 2017 38,357
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 46,325
PP_PREV Total number of people in the target population 2017 352,715
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 51
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 9
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 120
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 184
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 184
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 920
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 46
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 782
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 92
TB_SCREENDX Screen Result: Screened Positive for TB 2017 920
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 2,305
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 2,044
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 132
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 117
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 4,598
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 39
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 515
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 90
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,201
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,845
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,845
TX_CURR Aggregated Age/Sex: <15 Female 2017 139
TX_CURR Aggregated Age/Sex: <15 Male 2017 123
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,426
TX_CURR Aggregated Age/Sex: 15+ Male 2017 2,152
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 4,840
TX_CURR Sum of Aggregated Age/Sex <15 2017 262
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 4,578
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 4,840
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 8
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 7
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 749
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 664
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,428
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,428
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 883
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 662
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 4
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 3
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 351
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 304
TX_PVLS Numerator: Indication: Routine 2017 629
TX_PVLS Numerator: Indication: Targeted 2017 33
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 4
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 468
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 406
TX_PVLS_den Denominator: Indication: Routine 2017 836
TX_PVLS_den Denominator: Indication: Targeted 2017 47
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 624
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 541
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 1,177
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 1,453
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 770
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 668
Cross Cutting Budget Categories and Known Amounts Total: $200,000
Gender: Gender Based Violence (GBV) $200,000
GBV Prevention
Implementation
Monitoring and Evaluation
Post GBV Care
Implementation
Monitoring and Evaluation